APO Research
Talk to an analyst

APO RESEARCH · REPORT

Microbial API

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Microbial API Market Outlook and Growth Opportunities 2026

21 December 2025192 pages

Choose your research edition.

Industry ResearchMicrobial API Industry Research Report 2026118 pages · $2,950 USDIndustry Growth & TrendsGlobal Microbial API Industry Growth and Trends Forecast to 2032102 pages · $3,450 USDMarket StructureGlobal Microbial API Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032190 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Microbial API Market Outlook and Growth Opportunities 2026192 pages · $4,250 USDMarket Analysis & ForecastGlobal Microbial API Market Analysis and Forecast 2026-2032197 pages · $4,950 USD

Market perspective

The global Microbial API market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Microbial API is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Microbial API is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Microbial API is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Microbial API market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Microbial API market include DSM, Tianjin Tianyao Pharmaceuticals Co., Ltd., Merck & Co., Inc., Luwei Pharmaceutical Group Co., Ltd., Shandong Lukang Pharmaceutical Co., Ltd., Huaxing, North China Pharmaceutical Co Ltd, Topfond Pharmaceutical Co., Ltd. and Northeast Pharm, among others. In 2025, the top three vendors together accounted for approximately % of global market revenue.

This report provides an overview of the global Microbial API market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Microbial API and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Microbial API revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global Microbial API market.

Microbial API Segment by Company

DSM

Tianjin Tianyao Pharmaceuticals Co., Ltd.

Merck & Co., Inc.

Luwei Pharmaceutical Group Co., Ltd.

Shandong Lukang Pharmaceutical Co., Ltd.

Huaxing

North China Pharmaceutical Co Ltd

Topfond Pharmaceutical Co., Ltd.

Northeast Pharm

KOLON LIFE SCIENCE

HGPF

CSPC Pharma

Microbial API Segment by Type

Amino acids

Hormones

Nucleotides

Antibiotics

Vitamins

Organic Acids

Microbial API Segment by Application

Pharmaceutical and Biotechnology Companies

Hospitals

Research and Academic Laboratories

Microbial API Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Microbial API status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the Microbial API key companies, revenue, market share, and recent developments.

3. To split the Microbial API breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions Microbial API market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Microbial API significant trends, drivers, influence factors in global and regions.

6. To analyze Microbial API competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Microbial API market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Microbial API and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Microbial API.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Microbial API industry.

Chapter 3: Detailed analysis of Microbial API company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of Microbial API in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of Microbial API in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Microbial API Industry Trends Table 2. Microbial API Industry Drivers Table 3. Microbial API Industry Opportunities and Challenges Table 4. Microbial API Industry Restraints Table 5. Global Microbial API Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Microbial API Revenue Share by Company (2021-2026) Table 7. Global Microbial API Company Ranking, (2024-2026) & (US$ Million) Table 8. Global Microbial API Key Company Manufacturing Base & Headquarters Table 9. Global Microbial API Company, Product Type & Application Table 10. Global Microbial API Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global Microbial API by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of Amino acids Table 15. Significant Companies of Hormones Table 16. Significant Companies of Nucleotides Table 17. Significant Companies of Antibiotics Table 18. Significant Companies of Vitamins Table 19. Significant Companies of Organic Acids Table 20. Global Microbial API Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 21. Global Microbial API Sales Value by Type (2021-2026) & (US$ Million) Table 22. Global Microbial API Sales Value by Type (2027-2032) & (US$ Million) Table 23. Global Microbial API Sales Value Share by Type (2021-2026) Table 24. Global Microbial API Sales Value Share by Type (2027-2032) Table 25. Significant Companies of Pharmaceutical and Biotechnology Companies Table 26. Significant Companies of Hospitals Table 27. Significant Companies of Research and Academic Laboratories Table 28. Global Microbial API Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 29. Global Microbial API Sales Value by Application (2021-2026) & (US$ Million) Table 30. Global Microbial API Sales Value by Application (2027-2032) & (US$ Million) Table 31. Global Microbial API Sales Value Share by Application (2021-2026) Table 32. Global Microbial API Sales Value Share by Application (2027-2032) Table 33. Global Microbial API Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 34. Global Microbial API Sales Value by Region (2021-2026) & (US$ Million) Table 35. Global Microbial API Sales Value Share by Region (2021-2026) Table 36. Global Microbial API Sales Value by Region (2027-2032) & (US$ Million) Table 37. Global Microbial API Sales Value Share by Region (2027-2032) Table 38. Global Microbial API Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 39. Global Microbial API Sales Value by Country (2021-2026) & (US$ Million) Table 40. Global Microbial API Sales Value Market Share by Country (2021-2026) Table 41. Global Microbial API Sales Value by Country (2027-2032) & (US$ Million) Table 42. Global Microbial API Sales Value Market Share by Country (2027-2032) Table 43. DSM Company Information Table 44. DSM Business Overview Table 45. DSM Microbial API Revenue (US$ Million) and Gross Margin (2021-2026) Table 46. DSM Microbial API Product Portfolio Table 47. DSM Recent Development Table 48. Tianjin Tianyao Pharmaceuticals Co., Ltd. Company Information Table 49. Tianjin Tianyao Pharmaceuticals Co., Ltd. Business Overview Table 50. Tianjin Tianyao Pharmaceuticals Co., Ltd. Microbial API Revenue (US$ Million) and Gross Margin (2021-2026) Table 51. Tianjin Tianyao Pharmaceuticals Co., Ltd. Microbial API Product Portfolio Table 52. Tianjin Tianyao Pharmaceuticals Co., Ltd. Recent Development Table 53. Merck & Co., Inc. Company Information Table 54. Merck & Co., Inc. Business Overview Table 55. Merck & Co., Inc. Microbial API Revenue (US$ Million) and Gross Margin (2021-2026) Table 56. Merck & Co., Inc. Microbial API Product Portfolio Table 57. Merck & Co., Inc. Recent Development Table 58. Luwei Pharmaceutical Group Co., Ltd. Company Information Table 59. Luwei Pharmaceutical Group Co., Ltd. Business Overview Table 60. Luwei Pharmaceutical Group Co., Ltd. Microbial API Revenue (US$ Million) and Gross Margin (2021-2026) Table 61. Luwei Pharmaceutical Group Co., Ltd. Microbial API Product Portfolio Table 62. Luwei Pharmaceutical Group Co., Ltd. Recent Development Table 63. Shandong Lukang Pharmaceutical Co., Ltd. Company Information Table 64. Shandong Lukang Pharmaceutical Co., Ltd. Business Overview Table 65. Shandong Lukang Pharmaceutical Co., Ltd. Microbial API Revenue (US$ Million) and Gross Margin (2021-2026) Table 66. Shandong Lukang Pharmaceutical Co., Ltd. Microbial API Product Portfolio Table 67. Shandong Lukang Pharmaceutical Co., Ltd. Recent Development Table 68. Huaxing Company Information Table 69. Huaxing Business Overview Table 70. Huaxing Microbial API Revenue (US$ Million) and Gross Margin (2021-2026) Table 71. Huaxing Microbial API Product Portfolio Table 72. Huaxing Recent Development Table 73. North China Pharmaceutical Co Ltd Company Information Table 74. North China Pharmaceutical Co Ltd Business Overview Table 75. North China Pharmaceutical Co Ltd Microbial API Revenue (US$ Million) and Gross Margin (2021-2026) Table 76. North China Pharmaceutical Co Ltd Microbial API Product Portfolio Table 77. North China Pharmaceutical Co Ltd Recent Development Table 78. Topfond Pharmaceutical Co., Ltd. Company Information Table 79. Topfond Pharmaceutical Co., Ltd. Business Overview Table 80. Topfond Pharmaceutical Co., Ltd. Microbial API Revenue (US$ Million) and Gross Margin (2021-2026) Table 81. Topfond Pharmaceutical Co., Ltd. Microbial API Product Portfolio Table 82. Topfond Pharmaceutical Co., Ltd. Recent Development Table 83. Northeast Pharm Company Information Table 84. Northeast Pharm Business Overview Table 85. Northeast Pharm Microbial API Revenue (US$ Million) and Gross Margin (2021-2026) Table 86. Northeast Pharm Microbial API Product Portfolio Table 87. Northeast Pharm Recent Development Table 88. KOLON LIFE SCIENCE Company Information Table 89. KOLON LIFE SCIENCE Business Overview Table 90. KOLON LIFE SCIENCE Microbial API Revenue (US$ Million) and Gross Margin (2021-2026) Table 91. KOLON LIFE SCIENCE Microbial API Product Portfolio Table 92. KOLON LIFE SCIENCE Recent Development Table 93. HGPF Company Information Table 94. HGPF Business Overview Table 95. HGPF Microbial API Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 96. HGPF Microbial API Product Portfolio Table 97. HGPF Recent Development Table 98. CSPC Pharma Company Information Table 99. CSPC Pharma Business Overview Table 100. CSPC Pharma Microbial API Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 101. CSPC Pharma Microbial API Product Portfolio Table 102. CSPC Pharma Recent Development Table 103. Research Programs/Design for This Report Table 104. Authors List of This Report Table 105. Secondary Sources Table 106. Primary Sources List of Figures Figure 1. Microbial API Product Image Figure 2. Global Microbial API Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Microbial API Market Size (2021-2032) & (US$ Million) Figure 4. Global Microbial API Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. Amino acids Image Figure 8. Hormones Image Figure 9. Nucleotides Image Figure 10. Antibiotics Image Figure 11. Vitamins Image Figure 12. Organic Acids Image Figure 13. Global Microbial API Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 14. Global Microbial API Sales Value Share 2021 VS 2025 VS 2032 Figure 15. Global Microbial API Sales Value Share by Type (2021-2032) Figure 16. Pharmaceutical and Biotechnology Companies Image Figure 17. Hospitals Image Figure 18. Research and Academic Laboratories Image Figure 19. Global Microbial API Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 20. Global Microbial API Sales Value Share 2021 VS 2025 VS 2032 Figure 21. Global Microbial API Sales Value Share by Application (2021-2032) Figure 22. Global Microbial API Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 23. Global Microbial API Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 24. North America Microbial API Sales Value (2021-2032) & (US$ Million) Figure 25. North America Microbial API Sales Value Share by Country (%), 2025 VS 2032 Figure 26. Europe Microbial API Sales Value (2021-2032) & (US$ Million) Figure 27. Europe Microbial API Sales Value Share by Country (%), 2025 VS 2032 Figure 28. Asia-Pacific Microbial API Sales Value (2021-2032) & (US$ Million) Figure 29. Asia-Pacific Microbial API Sales Value Share by Country (%), 2025 VS 2032 Figure 30. South America Microbial API Sales Value (2021-2032) & (US$ Million) Figure 31. South America Microbial API Sales Value Share by Country (%), 2025 VS 2032 Figure 32. Middle East & Africa Microbial API Sales Value (2021-2032) & (US$ Million) Figure 33. Middle East & Africa Microbial API Sales Value Share by Country (%), 2025 VS 2032 Figure 34. USA Microbial API Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 35. USA Microbial API Sales Value Share by Type, 2025 VS 2032 & (%) Figure 36. USA Microbial API Sales Value Share by Application, 2025 VS 2032 & (%) Figure 37. Canada Microbial API Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 38. Canada Microbial API Sales Value Share by Type, 2025 VS 2032 & (%) Figure 39. Canada Microbial API Sales Value Share by Application, 2025 VS 2032 & (%) Figure 40. Mexico Microbial API Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 41. Mexico Microbial API Sales Value Share by Type, 2025 VS 2032 & (%) Figure 42. Mexico Microbial API Sales Value Share by Application, 2025 VS 2032 & (%) Figure 43. Germany Microbial API Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 44. Germany Microbial API Sales Value Share by Type, 2025 VS 2032 & (%) Figure 45. Germany Microbial API Sales Value Share by Application, 2025 VS 2032 & (%) Figure 46. France Microbial API Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 47. France Microbial API Sales Value Share by Type, 2025 VS 2032 & (%) Figure 48. France Microbial API Sales Value Share by Application, 2025 VS 2032 & (%) Figure 49. U.K. Microbial API Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 50. U.K. Microbial API Sales Value Share by Type, 2025 VS 2032 & (%) Figure 51. U.K. Microbial API Sales Value Share by Application, 2025 VS 2032 & (%) Figure 52. Italy Microbial API Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 53. Italy Microbial API Sales Value Share by Type, 2025 VS 2032 & (%) Figure 54. Italy Microbial API Sales Value Share by Application, 2025 VS 2032 & (%) Figure 55. Spain Microbial API Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 56. Spain Microbial API Sales Value Share by Type, 2025 VS 2032 & (%) Figure 57. Spain Microbial API Sales Value Share by Application, 2025 VS 2032 & (%) Figure 58. Russia Microbial API Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 59. Russia Microbial API Sales Value Share by Type, 2025 VS 2032 & (%) Figure 60. Russia Microbial API Sales Value Share by Application, 2025 VS 2032 & (%) Figure 61. Netherlands Microbial API Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 62. Netherlands Microbial API Sales Value Share by Type, 2025 VS 2032 & (%) Figure 63. Netherlands Microbial API Sales Value Share by Application, 2025 VS 2032 & (%) Figure 64. Nordic Countries Microbial API Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 65. Nordic Countries Microbial API Sales Value Share by Type, 2025 VS 2032 & (%) Figure 66. Nordic Countries Microbial API Sales Value Share by Application, 2025 VS 2032 & (%) Figure 67. China Microbial API Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 68. China Microbial API Sales Value Share by Type, 2025 VS 2032 & (%) Figure 69. China Microbial API Sales Value Share by Application, 2025 VS 2032 & (%) Figure 70. Japan Microbial API Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 71. Japan Microbial API Sales Value Share by Type, 2025 VS 2032 & (%) Figure 72. Japan Microbial API Sales Value Share by Application, 2025 VS 2032 & (%) Figure 73. South Korea Microbial API Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 74. South Korea Microbial API Sales Value Share by Type, 2025 VS 2032 & (%) Figure 75. South Korea Microbial API Sales Value Share by Application, 2025 VS 2032 & (%) Figure 76. India Microbial API Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 77. India Microbial API Sales Value Share by Type, 2025 VS 2032 & (%) Figure 78. India Microbial API Sales Value Share by Application, 2025 VS 2032 & (%) Figure 79. Australia Microbial API Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 80. Australia Microbial API Sales Value Share by Type, 2025 VS 2032 & (%) Figure 81. Australia Microbial API Sales Value Share by Application, 2025 VS 2032 & (%) Figure 82. Southeast Asia Microbial API Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 83. Southeast Asia Microbial API Sales Value Share by Type, 2025 VS 2032 & (%) Figure 84. Southeast Asia Microbial API Sales Value Share by Application, 2025 VS 2032 & (%) Figure 85. Brazil Microbial API Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 86. Brazil Microbial API Sales Value Share by Type, 2025 VS 2032 & (%) Figure 87. Brazil Microbial API Sales Value Share by Application, 2025 VS 2032 & (%) Figure 88. Argentina Microbial API Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 89. Argentina Microbial API Sales Value Share by Type, 2025 VS 2032 & (%) Figure 90. Argentina Microbial API Sales Value Share by Application, 2025 VS 2032 & (%) Figure 91. Chile Microbial API Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 92. Chile Microbial API Sales Value Share by Type, 2025 VS 2032 & (%) Figure 93. Chile Microbial API Sales Value Share by Application, 2025 VS 2032 & (%) Figure 94. Colombia Microbial API Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 95. Colombia Microbial API Sales Value Share by Type, 2025 VS 2032 & (%) Figure 96. Colombia Microbial API Sales Value Share by Application, 2025 VS 2032 & (%) Figure 97. Peru Microbial API Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 98. Peru Microbial API Sales Value Share by Type, 2025 VS 2032 & (%) Figure 99. Peru Microbial API Sales Value Share by Application, 2025 VS 2032 & (%) Figure 100. Saudi Arabia Microbial API Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 101. Saudi Arabia Microbial API Sales Value Share by Type, 2025 VS 2032 & (%) Figure 102. Saudi Arabia Microbial API Sales Value Share by Application, 2025 VS 2032 & (%) Figure 103. Israel Microbial API Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 104. Israel Microbial API Sales Value Share by Type, 2025 VS 2032 & (%) Figure 105. Israel Microbial API Sales Value Share by Application, 2025 VS 2032 & (%) Figure 106. UAE Microbial API Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 107. UAE Microbial API Sales Value Share by Type, 2025 VS 2032 & (%) Figure 108. UAE Microbial API Sales Value Share by Application, 2025 VS 2032 & (%) Figure 109. Turkey Microbial API Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 110. Turkey Microbial API Sales Value Share by Type, 2025 VS 2032 & (%) Figure 111. Turkey Microbial API Sales Value Share by Application, 2025 VS 2032 & (%) Figure 112. Iran Microbial API Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 113. Iran Microbial API Sales Value Share by Type, 2025 VS 2032 & (%) Figure 114. Iran Microbial API Sales Value Share by Application, 2025 VS 2032 & (%) Figure 115. Egypt Microbial API Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 116. Egypt Microbial API Sales Value Share by Type, 2025 VS 2032 & (%) Figure 117. Egypt Microbial API Sales Value Share by Application, 2025 VS 2032 & (%) Figure 118. Years Considered Figure 119. Research Process Figure 120. Key Executives Interviewed

Scope & coverage.

Types
  • Amino acids
  • Hormones
  • Nucleotides
  • Antibiotics
  • Vitamins
  • Organic Acids
Applications
  • Pharmaceutical and Biotechnology Companies
  • Hospitals
  • Research and Academic Laboratories
Companies covered
  • DSM
  • Tianjin Tianyao Pharmaceuticals Co., Ltd.
  • Merck & Co., Inc.
  • Luwei Pharmaceutical Group Co., Ltd.
  • Shandong Lukang Pharmaceutical Co., Ltd.
  • Huaxing
  • North China Pharmaceutical Co Ltd
  • Topfond Pharmaceutical Co., Ltd.
  • Northeast Pharm
  • KOLON LIFE SCIENCE
  • HGPF
  • CSPC Pharma

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Microbial API Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Microbial API Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 Microbial API Market Dynamics
  1. 2.1 Microbial API Industry Trends
  2. 2.2 Microbial API Industry Drivers
  3. 2.3 Microbial API Industry Opportunities and Challenges
  4. 2.4 Microbial API Industry Restraints
3 Microbial API Market by Company
  1. 3.1 Global Microbial API Company Revenue Ranking in 2025
  2. 3.2 Global Microbial API Revenue by Company (2021-2026)
  3. 3.3 Global Microbial API Company Ranking (2024-2026)
  4. 3.4 Global Microbial API Company Manufacturing Base and Headquarters
  5. 3.5 Global Microbial API Company Product Type and Application
  6. 3.6 Global Microbial API Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global Microbial API Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 Microbial API Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 Microbial API Market by Type
  1. 4.1 Microbial API Type Introduction
  2. 4.1.1 Amino acids
  3. 4.1.2 Hormones
  4. 4.1.3 Nucleotides
  5. 4.1.4 Antibiotics
  6. 4.1.5 Vitamins
  7. 4.1.6 Organic Acids
  8. 4.2 Global Microbial API Sales Value by Type
  9. 4.2.1 Global Microbial API Sales Value by Type (2021 VS 2025 VS 2032)
  10. 4.2.2 Global Microbial API Sales Value by Type (2021-2032)
  11. 4.2.3 Global Microbial API Sales Value Share by Type (2021-2032)
5 Microbial API Market by Application
  1. 5.1 Microbial API Application Introduction
  2. 5.1.1 Pharmaceutical and Biotechnology Companies
  3. 5.1.2 Hospitals
  4. 5.1.3 Research and Academic Laboratories
  5. 5.2 Global Microbial API Sales Value by Application
  6. 5.2.1 Global Microbial API Sales Value by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Microbial API Sales Value by Application (2021-2032)
  8. 5.2.3 Global Microbial API Sales Value Share by Application (2021-2032)
6 Microbial API Regional Value Analysis
  1. 6.1 Global Microbial API Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Microbial API Sales Value by Region (2021-2032)
  3. 6.2.1 Global Microbial API Sales Value by Region: 2021-2026
  4. 6.2.2 Global Microbial API Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Microbial API Sales Value (2021-2032)
  7. 6.3.2 North America Microbial API Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe Microbial API Sales Value (2021-2032)
  10. 6.4.2 Europe Microbial API Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific Microbial API Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific Microbial API Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America Microbial API Sales Value (2021-2032)
  16. 6.6.2 South America Microbial API Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa Microbial API Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa Microbial API Sales Value Share by Country, 2025 VS 2032
7 Microbial API Country-level Value Analysis
  1. 7.1 Global Microbial API Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Microbial API Sales Value by Country (2021-2032)
  3. 7.2.1 Global Microbial API Sales Value by Country (2021-2026)
  4. 7.2.2 Global Microbial API Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA Microbial API Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA Microbial API Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA Microbial API Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada Microbial API Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada Microbial API Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada Microbial API Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico Microbial API Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico Microbial API Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico Microbial API Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany Microbial API Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany Microbial API Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany Microbial API Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France Microbial API Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France Microbial API Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France Microbial API Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. Microbial API Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. Microbial API Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. Microbial API Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy Microbial API Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy Microbial API Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy Microbial API Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain Microbial API Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain Microbial API Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain Microbial API Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia Microbial API Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia Microbial API Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia Microbial API Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands Microbial API Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands Microbial API Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands Microbial API Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries Microbial API Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries Microbial API Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries Microbial API Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China Microbial API Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China Microbial API Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China Microbial API Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan Microbial API Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan Microbial API Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan Microbial API Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea Microbial API Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea Microbial API Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea Microbial API Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India Microbial API Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India Microbial API Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India Microbial API Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia Microbial API Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia Microbial API Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia Microbial API Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia Microbial API Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia Microbial API Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia Microbial API Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil Microbial API Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil Microbial API Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil Microbial API Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina Microbial API Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina Microbial API Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina Microbial API Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile Microbial API Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile Microbial API Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile Microbial API Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia Microbial API Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia Microbial API Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia Microbial API Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru Microbial API Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru Microbial API Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru Microbial API Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia Microbial API Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia Microbial API Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia Microbial API Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel Microbial API Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel Microbial API Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel Microbial API Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE Microbial API Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE Microbial API Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE Microbial API Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey Microbial API Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey Microbial API Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey Microbial API Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran Microbial API Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran Microbial API Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran Microbial API Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt Microbial API Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt Microbial API Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt Microbial API Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 DSM
  2. 8.1.1 DSM Company Information
  3. 8.1.2 DSM Business Overview
  4. 8.1.3 DSM Microbial API Revenue and Gross Margin (2021-2026)
  5. 8.1.4 DSM Microbial API Product Portfolio
  6. 8.1.5 DSM Recent Developments
  7. 8.2 Tianjin Tianyao Pharmaceuticals Co., Ltd.
  8. 8.2.1 Tianjin Tianyao Pharmaceuticals Co., Ltd. Company Information
  9. 8.2.2 Tianjin Tianyao Pharmaceuticals Co., Ltd. Business Overview
  10. 8.2.3 Tianjin Tianyao Pharmaceuticals Co., Ltd. Microbial API Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Tianjin Tianyao Pharmaceuticals Co., Ltd. Microbial API Product Portfolio
  12. 8.2.5 Tianjin Tianyao Pharmaceuticals Co., Ltd. Recent Developments
  13. 8.3 Merck & Co., Inc.
  14. 8.3.1 Merck & Co., Inc. Company Information
  15. 8.3.2 Merck & Co., Inc. Business Overview
  16. 8.3.3 Merck & Co., Inc. Microbial API Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Merck & Co., Inc. Microbial API Product Portfolio
  18. 8.3.5 Merck & Co., Inc. Recent Developments
  19. 8.4 Luwei Pharmaceutical Group Co., Ltd.
  20. 8.4.1 Luwei Pharmaceutical Group Co., Ltd. Company Information
  21. 8.4.2 Luwei Pharmaceutical Group Co., Ltd. Business Overview
  22. 8.4.3 Luwei Pharmaceutical Group Co., Ltd. Microbial API Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Luwei Pharmaceutical Group Co., Ltd. Microbial API Product Portfolio
  24. 8.4.5 Luwei Pharmaceutical Group Co., Ltd. Recent Developments
  25. 8.5 Shandong Lukang Pharmaceutical Co., Ltd.
  26. 8.5.1 Shandong Lukang Pharmaceutical Co., Ltd. Company Information
  27. 8.5.2 Shandong Lukang Pharmaceutical Co., Ltd. Business Overview
  28. 8.5.3 Shandong Lukang Pharmaceutical Co., Ltd. Microbial API Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Shandong Lukang Pharmaceutical Co., Ltd. Microbial API Product Portfolio
  30. 8.5.5 Shandong Lukang Pharmaceutical Co., Ltd. Recent Developments
  31. 8.6 Huaxing
  32. 8.6.1 Huaxing Company Information
  33. 8.6.2 Huaxing Business Overview
  34. 8.6.3 Huaxing Microbial API Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Huaxing Microbial API Product Portfolio
  36. 8.6.5 Huaxing Recent Developments
  37. 8.7 North China Pharmaceutical Co Ltd
  38. 8.7.1 North China Pharmaceutical Co Ltd Company Information
  39. 8.7.2 North China Pharmaceutical Co Ltd Business Overview
  40. 8.7.3 North China Pharmaceutical Co Ltd Microbial API Revenue and Gross Margin (2021-2026)
  41. 8.7.4 North China Pharmaceutical Co Ltd Microbial API Product Portfolio
  42. 8.7.5 North China Pharmaceutical Co Ltd Recent Developments
  43. 8.8 Topfond Pharmaceutical Co., Ltd.
  44. 8.8.1 Topfond Pharmaceutical Co., Ltd. Company Information
  45. 8.8.2 Topfond Pharmaceutical Co., Ltd. Business Overview
  46. 8.8.3 Topfond Pharmaceutical Co., Ltd. Microbial API Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Topfond Pharmaceutical Co., Ltd. Microbial API Product Portfolio
  48. 8.8.5 Topfond Pharmaceutical Co., Ltd. Recent Developments
  49. 8.9 Northeast Pharm
  50. 8.9.1 Northeast Pharm Company Information
  51. 8.9.2 Northeast Pharm Business Overview
  52. 8.9.3 Northeast Pharm Microbial API Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Northeast Pharm Microbial API Product Portfolio
  54. 8.9.5 Northeast Pharm Recent Developments
  55. 8.10 KOLON LIFE SCIENCE
  56. 8.10.1 KOLON LIFE SCIENCE Company Information
  57. 8.10.2 KOLON LIFE SCIENCE Business Overview
  58. 8.10.3 KOLON LIFE SCIENCE Microbial API Revenue and Gross Margin (2021-2026)
  59. 8.10.4 KOLON LIFE SCIENCE Microbial API Product Portfolio
  60. 8.10.5 KOLON LIFE SCIENCE Recent Developments
  61. 8.11 HGPF
  62. 8.11.1 HGPF Company Information
  63. 8.11.2 HGPF Business Overview
  64. 8.11.3 HGPF Microbial API Revenue and Gross Margin (2021-2026)
  65. 8.11.4 HGPF Microbial API Product Portfolio
  66. 8.11.5 HGPF Recent Developments
  67. 8.12 CSPC Pharma
  68. 8.12.1 CSPC Pharma Company Information
  69. 8.12.2 CSPC Pharma Business Overview
  70. 8.12.3 CSPC Pharma Microbial API Revenue and Gross Margin (2021-2026)
  71. 8.12.4 CSPC Pharma Microbial API Product Portfolio
  72. 8.12.5 CSPC Pharma Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst